Tumor Necrosis Factor Inhibitors and Lung Disease: A Paradox of Efficacy and Risk

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 2, 2010, Pages 147-163

  Khasnis, Atul A ^a   Calabrese, Leonard H ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Granuloma; Pulmonary fibrosis; Sarcoidosis; Toxicity; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; SALAZOSULFAPYRIDINE; STEROID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ANTISYNTHETASE SYNDROME; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EPITHELIOID SARCOMA; FIBROSING ALVEOLITIS; GRANULOMA; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LUNG DISEASE; LUNG EMBOLISM; LUNG FIBROSIS; LUNG GRANULOMATOSIS; LUNG HEMORRHAGE; LUNG SARCOIDOSIS; LUNG SQUAMOUS CELL CARCINOMA; NONHUMAN; PNEUMONIA; POLYMYOSITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SARCOIDOSIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC SCLEROSIS; THROMBOSIS;

ANTIRHEUMATIC AGENTS; DATABASES, FACTUAL; HUMANS; LUNG DISEASES; RHEUMATIC DISEASES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957020350     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2009.09.001     Document Type: Review

References (130)

1. Rychly D.J., DiPiro J.T. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005, 25(9):1181-1192.
2. Desai S.B., Furst D.E. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006, 20(4):757-790.
3. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells. Nature 1997, 385:729-733.
4. Zhao J., Chen H., Peschon J.J., Shi W., Zhang Y., Frank S.J., et al. Pulmonary Hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev Biol 2001, 232(1):204-218.
5. Trautmann A., Kruger K., Akdis M., Muller-Wening D., Akkaya A., Brocker E.B., et al. Apoptosis and loss of adhesion of bronchial epithelial cells in asthma. Int Arch Allergy Immunol 2005, 138(2):142-150.
6. Kampf C., Relova A.J., Sandler S., Roomans G.M. Effects of TNF-alpha, IFN-gamma and IL-beta on normal human bronchial epithelial cells. Eur Respir J 1999, 14(1):84-91.
7. Sun M., Fink P.J. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol 2007, 179(7):4307-4312.
8. Vilcek J., Tsujimoto M., Palombella V.J., Kohase M., Le J. Tumor necrosis factor: receptor binding and mitogenic action in fibroblasts. J Cell Physiol Suppl 1987, (Suppl 5):57-61.
9. Ermert M., Pantazis C., Duncker H.R., Grimminger F., Seeger W., Ermert L. In situ localization of TNF alpha/beta. TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. Cytokine 2003, 22(3-4):89-100.
10. Mazzon E., Cuzzocrea S. Role of TNF-alpha in lung tight junction alteration in mouse model of acute lung inflammation. Respir Res 2007, 8:75.
11. Borron P., McIntosh J.C., Korfhagen T.R., Whitsett J.A., Taylor J., Wright J.R. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol 2000, 278(4):L840-L847.
12. Miakotina O.L., Snyder J.M. TNF-alpha inhibits SP-A gene expression in lung epithelial cells via p38 MAPK. Am J Physiol Lung Cell Mol Physiol 2002, 283(2):L418-L427.
13. Ventura J.J., Hübner A., Zhang C., Flavell R.A., Shokat K.M., Davis R.J. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 2006, 21(5):701-710.
14. Mong P.Y., Petrulio C., Kaufman H.L., Wang Q. Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells. J Immunol 2008, 180(1):550-558.
15. Wagner E.M. TNF-alpha induced bronchial vasoconstriction. Am J Physiol Heart Circ Physiol 2000, 279(3):H946-H951.
16. Lundblad L.K., Thompson-Figueroa J., Leclair T., Sullivan M.J., Poynter M.E., Irvin G., et al. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005, 171(12):1363-1370.
17. Chung K.F. Cytokines in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 2005, 4(6):619-625.
18. Ishii Y., Partridge C.A., Del Vecchio P.J., Malik A.B. Tumor necrosis factor-alpha-mediated decrease in glutathione increases the sensitivity of pulmonary vascular endothelial cells to H2O2. J Clin Invest 1992, 89(3):794-802.
19. Corda S., Laplace C., Vicaut E., Duranteau J. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol 2001, 24(6):762-768.
20. Van de Vosse E., van Agtmael M.A. Targets of anticytokine therapy and the risk of infections in humans and mice. Curr Opin Rheumatol 2007, 19(6):626-635.
21. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999, 162(6):3504-3511.
22. Saunders B.M., Cooper A.M. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol 2000, 78(4):334-341.
23. Chensue S.W., Warmington K., Ruth J., Lincoln P., Kuo M.C., Kunkel S.L. Cytokine responses during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Production of Th1 and Th2 cytokines and relative contribution of tumor necrosis factor. Am J Pathol 1994, 145(5):1105-1113.
24. Mustafa T., Mogga S.J., Mfinanga S.G., Mørkve O., Sviland L. Immunohistochemical analysis of cytokines and apoptosis in tuberculous lymphadenitis. Immunology 2006, 117(4):454-462.
25. Fenhalls G., Stevens L., Bezuidenhout J., Amphlett G.E., Duncan K., Bardin P., et al. Distribution of IFN-gamma. IL-4 and TNF-alpha protein and CD8 T cells producing IL-12p40 mRNA in human lung tuberculous granulomas. Immunology 2002, 105(3):325-335.
26. Fenhalls G., Wong A., Bezuidenhout J., van Helden P., Bardin P., Lukey P.T. In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas. Infect Immun 2000, 68(5):2827-2836.
27. Ridley M.J., Heather C.J., Brown I., Willoughby D.A. Experimental epithelioid cell granulomas, tubercle formation and immunological competence: an ultrastructural analysis. J Pathol 1983, 141(2):97-112.
28. Baumer I., Zissel G., Schlaak M., Muller-Quernheim J. Th1/Th2 cell distribution in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1997, 16:171-177.
29. Fehrenbach H., Zissel G., Goldmann T., Tschernig T., Vollmer E., Pabst R., et al. Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J 2003, 21:421-428.
30. Sharma S., Ghosh B., Sharma S.K. Association of TNF polymorphisms with sarcoidosis, its prognosis and tumour necrosis factor (TNF)-alpha levels in Asian Indians. Clin Exp Immunol 2008, 151(2):251-259.
31. Loike J.D., Silverstein R., Wright S.D., Weitz J.I., Huang A.J., Silverstein S.C. The role of protected extracellular compartments in interactions between leukocytes, and platelets, and fibrin/fibrinogen matrices. Ann NY Acad Sci 1992, 667:163-172.
32. Heppleston A.G., Styles J.A. Activity of a macrophage factor in collagen formation by silica. Nature 1967, 214:521-522.
33. Leibovich S.J., Ross R. A macrophage-dependant factor that stimulates the proliferation of fibroblasts in vitro. Am J Pathol 1976, 84:501-513.
34. Goldstein E. Hydrolytic enzymes of alveolar macrophages. Rev Infect Dis 1983, 5(6):1078-1092.
35. Hampson F., Monick M., Peterson M.W., Hunninghake G.W. Immune mediators increase adherence of T-lymphocytes to human lung fibroblasts. Am J Physiol 1989, 256(2 Pt. 1):C336-C340.
36. Piguet P.F., Collart M.A., Grau G.E., Sappino A.P., Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990, 344(6263):245-247.
37. Gauldie J., Jordana M., Cox G. Cytokines and pulmonary fibrosis. Thorax 1993, 48(9):931-935.
38. Phan S.H., Gharaee-Kermani M., McGarry B., Kunkel S.L., Wolber F.W. Regulation of rat pulmonary artery endothelial cell transforming growth factor-beta production by IL-1 beta and tumor necrosis factor-alpha. J Immunol 1992, 149(1):103-106.
39. Thornton S.C., Robbins J.M., Penny R., Breit S.N. Fibroblast growth factors in connective tissue disease associated interstitial lung disease. Clin Exp Immunol 1992, 90(3):447-452.
40. Distler J.H., Schett G., Gay S., Distler O. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 2008, 58(8):2228-2235.
41. Li Y.Y., Feng Y.Q., Kadokami T., McTiernan C.F., Draviam R., Watkins S.C., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 2000, 97(23):12746-12751.
42. Ouellet S., Yang H., Aubin R.A., Hawley R.G., Wenckebach G.F., Lemaire I. Bidirectional modulation of TNF-alpha production by alveolar macrophages in asbestos-induced pulmonary fibrosis. J Leukoc Biol 1993, 53(3):279-286.
43. Paulsson Y., Austgulen R., Hofsli E., Heldin C.H., Westermark B., Nissen-Meyer J. Tumor necrosis factor-induced expression of platelet-derived growth factor A-chain messenger RNA in fibroblasts. Exp Cell Res 1989, 180:490-496.
44. Takahashi S., Dunn M.A., Seifter S. Liver collagenase in murine schistosomiasis. Gastroenterology 1980, 78(6):1425-1431.
45. Schiltz J.R., Olds G.R., Kresina T.F., Mahmoud A.A. Effect of chemotherapy on hepatic collagen and glycosaminoglycan metabolism in Schistosoma mansoni-infected mice. Trans R Soc Trop Med Hyg 1988, 82(6):868-873.
46. Grimaud J.A., Boros D.L., Takiya C., Mathew R.C., Emonard H. Collagen isotypes, and fibronectin in granulomas of the liver and intestines of Schistosoma mansoni-infected mice. Am J Trop Med Hyg 1987, 37(2):335-344.
47. Gosset P., Tsicopoulos A., Wallaert B., Vannimenus C., Joseph M., Tonnel A.B., et al. Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 1991, 88(4):561-571.
48. Ohkawara Y., Yamauchi K., Tanno Y., Tamura G., Ohtani H., Nagura H., et al. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-α in sensitized lung tissue after IgE receptor triggering. Am J Respir Cell Mol Biol 1992, 7:385-392.
49. Deveci F., Muz M.H., Ilhan N., Kirkil G., Turgut T., Akpolat N. Evaluation of the anti-inflammatory effect of infliximab in a mouse model of acute asthma. Respirology 2008, 13(4):488-497.
50. Khalil-Saadeh C., Brown D.M., Chumney-Malacara J.C., Crow J. Infliximab therapy for rheumatoid arthritis (RA) induced significant control of asthma in patients with both RA and asthma or asthma/COPD in addition to improving RA status. J. Allergy Clin Immunol 2002, 109(Suppl 1):s243.
51. Berry M.A., Hargadon B., Shelley M., Parker D., Shaw D.E., Green R.H., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006, 354(7):697-708.
52. Erin E.M., Leaker B.R., Nicholson G.C., Tan A.J., Green L.M., Neighbour H., et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006, 174(7):753-762.
53. Wenzel S.E., Barnes P.J., Bleecker E.R., Bousquet J., Busse W., Dahlén S.E., et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179(7):549-558.
54. Erzurum S.C. Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006, 354(7):754-758.
55. Zhang C., Cai S., Chen P., Chen J.B., Wu J., Wu S.J., et al. Inhibition of tumor necrosis factor-alpha reduces alveolar septal cell apoptosis in passive smoking rats. Chin Med J (Engl) 2008, 121(7):597-601.
56. van der Vaart H., Koëter G.H., Postma D.S., Kauffman H.F., ten Hacken N.H. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172(4):465-469.
57. Rennard S.I., Fogarty C., Kelsen S., Long W., Ramsdell J., Allison J., et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(9):926-934.
58. Russo C., D'Angelo F., Polosa R. Study of infliximab treatment in smokers with COPD: what next?. Am J Respir Crit Care Med 2005, 172(12):1607-1608.
59. Barnes P. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:866-867.
60. Baughman R.P., Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18(1):70-74.
61. Yee A.M., Pochapin M.B. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001, 135(1):27-31.
62. Doty J.D., Mazur J.E., Judson M.A. Treatment of sarcoidosis with infliximab. Chest 2005, 127(3):1064-1071.
63. Ramos-Casals M., Brito-Zerón P., Muñoz S., Soto M.J. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008, 87(6):345-364. BIOGEAS STUDY Group.
64. Baughman R.P., Drent M., Kavuru M., Judson M.A., Costabel U., du Bois R., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174(7):795-802.
65. Rossman M.D., Newman L.S., Baughman R.P., Teirstein A., Weinberger S.E., Miller W., et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23(3):201-208.
66. Callejas-Rubio J.L., Ortego-Centeno N., Lopez-Perez L., Benticuaga M.N. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006, 25(4):596-597.
67. Khanna D., Liebling M.R., Louie J.S. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003, 30(8):1864-1867.
68. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124(1):177-185.
69. Piguet P.F., Ribaux C., Karpuz V., Grau G.E., Kapanci Y. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993, 143(3):651-655.
70. Vassallo R., Matteson E., Thomas C.F. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002, 122(3):1093-1096.
71. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J 708;24(4):708.
72. Antoniou K.M., Mamoulaki M., Malagari K., Kritikos H.D., Bouros D., Siafakas N.M., et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007, 25(1):23-28.
73. Braun-Moscovici Y., Markovits D., Rozin A., Toledano K., Nahir A.M., Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. Isr Med Assoc J 2008, 10(4):277-281.
74. Raghu G., Brown K.K., Costabel U., Cottin V., du Bois R.M., Lasky J.A., et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178(9):948-955.
75. Ramos-Casals M., Brito-Zerón P., Muñoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86(4):242-251.
76. Toussirot E., Pertuiset E., Kantelip B., Wendling D. Sarcoidosis during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008, 26(3):471-475.
77. Verschueren K., Van Essche E., Verschueren P., Taelman V., Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007, 26(11):1969-1971.
78. O'Shea F.D., Marras T.K., Inman R.D. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 2006, 55(6):978-981.
79. Kudrin A., Chilvers E.R., Ginawi A., Hazleman B.L., Griffiths M.H., Thiru S., et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol 2007, 34(3):648-649.
80. Louie G.H., Chitkara P., Ward M.M. Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis 2008, 67(6):896-898.
81. Ishiguro T., Takayanagi N., Kurashima K., Matsushita A., Harasawa K., Yoneda K., et al. Development of sarcoidosis during etanercept therapy. Intern Med 2008, 47(11):1021-1025.
82. González-López M.A., Blanco R., González-Vela M.C., Fernández-Llaca H., Rodríguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006, 55(5):817-820.
83. Farah R.E., Shay M.D. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy 2007, 27(10):1446-1448.
84. Phillips K., Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum 2005, 53(4):618-620.
85. Almodóvar R., Izquierdo M., Zarco P., Javier Quirós F., Mazzucchelli R., Steen B. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2007, 25(1):99-101.
86. Sweiss N.J., Baughman R.P. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?. J Rheumatol 2007, 34(11):2129-2131.
87. Casey M.B., Tazelaar H.D., Myers J.L., Hunninghake G.W., Kakar S., Kalra S.X., et al. Noninfectious lung pathology in patients with Crohn's disease. Am J Surg Pathol 2003, 27(2):213-219.
88. Fallahi S., Collins R.D., Miller R.K., Halla J.T. Coexistence of rheumatoid arthritis and sarcoidosis: difficulties encountered in the differential diagnosis of common manifestations. J Rheumatol 1984, 11(4):526-529.
89. Rozin A., Yigla M., Guralnik L., Keidar Z., Vlodavsky E., Rozenbaum M., et al. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy. Clin Rheumatol 2006, 25(3):384-388.
90. Inoue K., Takano H., Yanagisawa R., Yoshikawa T. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis. Chest 2003, 124(1):413-414.
91. Cuchacovich R., Espinoza C.G., Virk Z., Espinoza L.R. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?. J Clin Rheumatol 2008, 14(6):353-356.
92. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 2004, 33(4):276-277.
93. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 1266;329(7477):1266.
94. Tengstrand B., Ernestam S., Engvall I.L., Rydvald Y., Hafström I. TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports. Lakartidningen 2005, 102(49):3788-3790. 3793.
95. Lindsay K., Melsom R., Jacob B.K., Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 2006, 45(8):1048-1049.
96. Tournadre A., Ledoux-Eberst J., Poujol D., Dubost J.J., Ristori J.M., Soubrier M. Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine 2008, 75(2):215-218.
97. Hagiwara K., Sato T., Takagi-Kobayashi S., Hasegawa S., Shigihara N., Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007, 34(5):1151-1154.
98. Huggett M.T., Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006, 45(10):1312-1313.
99. Schoe A., van der Laan-Baalbergen N.E., Huizinga T.W., Breedveld F.C., van Laar J.M. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 2006, 55(1):157-159.
100. Villeneuve E., St-Pierre A., Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006, 33(6):1189-1193.
101. Mori S., Imamura F., Kiyofuji C., Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol 2006, 16(4):251-255.
102. Weatherhead M., Masson S., Bourke S.J., Gunn M.C., Burns G.P. Interstitial pneumonitis after infliximab therapy for Crohn's disease. Inflamm Bowel Dis 2006, 12(5):427-428.
103. Quintos-Macasa A.M., Quinet R. Enbrel-induced interstitial lung disease. South Med J 2006, 99(7):783-784.
104. Allanore Y., Devos-François G., Caramella C., Boumier P., Jounieaux V., Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006, 65(6):834-835.
105. Cairns A.P., Taggart A.J. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002, 71:101-105.
106. Wolfe F., Caplan L., Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007, 36(3):172-178.
107. BSRBR Newsletter August 2004 by BSRBR-published in BSR, 2005-08-31. http://www.bjdonline.org/default.aspx?contId=944.
108. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354(9194):1932-1939.
109. Garcia-Vicuña R., Ortiz A.M., Carmona L., Ibáñez M., Castrejón I., Laffón A. Inflammatory Interstitial Lung Disease in rheumatoid arthritis patients treated with biologic treatment. Incidence and mortality rates compared with patients non receiving biologics. Ann Rheum Dis 2005, 64(Suppl III):470.
110. Ryan J.G., Murphy E., Barry M. Biologic therapy: a countrywide survey of anti-TNF use and associated complications. Ann Rheum Dis 2006, 65(Suppl II):499.
111. Hyrich K., Symmons D., Watson K., Silman A. BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 2006, 65(7):895-898.
112. Pincus T., Sokka T. Uniform databases in early arthritis: specific measures to complement classification criteria and indices of clinical change. Clin Exp Rheumatol 2003, 21(5 Suppl 31):S79-S88.
113. Kramer N., Chuzhin Y., Kaufman L.D., Ritter J.M., Rosenstein E.D. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002, 47(6):670-671.
114. Courtney P.A., Alderdice J., Whitehead E.M. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2003, 49(4):617. author reply, 617-8.
115. Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006, 54(5):1435-1439.
116. Wright S.A., Brown K., McCracken D., Taggart A.J. The use of biologic agents for severe inflammatory arthritis in Northern Ireland. EULAR [FRI0017] Abstract Archive. http://www.abstracts2view.com/eular/sessionindex.php.
117. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59(6):762-784.
118. Ledingham J., Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005, 44(2):157-163. British Society for Rheumatology Standards, Guidelines and Audit Working Group.
119. Furst D.E., Keystone E.C., Kirkham B., Fleischmann R., Mease P., Breedveld F.C., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008, 67(Suppl III):iii2-iii25.
120. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161(2 Pt. 1):646-664. American Thoracic Society.
121. http://www.nice.org.uk/nicemedia/pdf/TA130guidance.pdf.
122. http://www.rxabbott.com/pdf/humira.pdf.
123. http://www.remicade.com/remicade/assets/HCP_PPI.pdf.
124. http://www.enbrel.com/pdf/enbrel_pi.pdf.
125. Leombruno J.P., Einarson T.R., Keystone E.C. Incidence and incidence density of death in controlled clinical trials of anti-TNF drugs in rheumatoid arthritis. Ann Rheum Dis 2005, 64(Suppl III):464.
126. Askling J., Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20(2):138-144.
127. Cambien B., Bergmeier W., Saffaripour S., Mitchell H.A., Wagner D.D. Antithrombotic activity of TNF-alpha. J Clin Invest 2003, 112(10):1589-1596.
128. Ferraro-Peyret C., Coury F., Tebib J.G., Bienvenu J., Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004, 6(6):R535-R543.
129. Panagi S., Palka W., Korelitz B.I., Taskin M., Lessnau K.D. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm Bowel Dis 2004, 10(3):274-277.
130. Musiał J., Undas A., Celińska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(12):1566-1568.